On Friday, Shares of Rite Aid Corporation (NYSE:RAD), gained 0.23% to $8.72.
The Rite Aid Foundation’s KidCents program will donate $1.3 million to Folds of Honor, a nonprofit organization based in Owasso, Okla., dedicated to providing educational scholarships to children of fallen or disabled veterans. The donation was declared in Owasso over Memorial Day weekend during Folds of Honor’s annual Patriot Cup Invitational, a golf tournament and gala celebrating our nation’s heroes and raising funds for Folds of Honor.
Folds of Honor was founded in 2007 by Major Dan Rooney, an F-16 fighter pilot in the Oklahoma Air National Guard who served three tours of duty in Iraq. Since its inception, Folds of Honor has raised more than $70 million and awarded nearly 8,000 scholarships to the family members of fallen or disabled veterans.
KidCents was developed by The Rite Aid Foundation to provide Rite Aid customers an opportunity to do even more to assist the kids in the communities Rite Aid serves. Through KidCents, members of Rite Aid’s wellness+ with Plenti program can round up their in-store or online purchases to the nearest dollar and give their change to one of more than 300 nonprofit organizations focused on improving the health and wellbeing of children.
In addition to the donation, Folds of Honor is also able to receive round-up donations from Rite Aid customers through the KidCents program.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
Shares of Gilead Sciences Inc. (NASDAQ:GILD), declined -0.51% to $112.27, during its last trading session.
Gilead Sciences, declared results from the Phase 3 clinical Study 119 of an investigational use of Zydelig® (idelalisib) in combination with ofatumumab in formerly-treated patients with chronic lymphocytic leukemia (CLL). In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab contrast to ofatumumab alone (hazard ratio (HR) = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001). Detailed results will be presented recently during a poster session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #7023).
Study 119 was a randomized, controlled, open-label Phase 3 study evaluating the efficacy and safety of Zydelig in combination with ofatumumab. The study enrolled 261 adult patients with formerly treated CLL whose disease had progressed less than 24 months following completion of preceding therapy, and had not formerly been refractory to ofatumumab. Eligible patients were randomized 2:1 to receive an ofatumumab 1,000 mg dosing regimen (12 infusions, first infusion 300mg) over 24 weeks plus Zydelig (150 mg) twice daily (n=174) continuously until disease progression or unacceptable toxicity or an ofatumumab 2,000 mg dosing regimen (12 infusions, first infusion 300mg) over 24 weeks (n=87).
The primary endpoint was progression-free survival (PFS), defined as the time from randomization to definitive disease progression or death assessed by an independent review committee. Median PFS in the Zydelig/ofatumumab arm was 16.3 months, contrast to 8.0 months in the ofatumumab monotherapy arm. Statistically noteworthy improvements were also observed for overall response rate (75 percent vs. 18 percent; odds ratio (OR) = 15.9, p<0.0001) and lymph node response rate (93.3 percent vs. 4.9 percent; OR=486.96, p<0.0001). Median PFS in the about 40 percent of patients with 17p deletion or TP53 mutation was 13.7 months vs. 5.8 months (HR=0.32, p<0.0001). A statistically noteworthy difference was not achieved in median overall survival (20.9 months vs. 19.4 months; HR=0.74, p=0.27).
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific.
At the end of Friday’s trade, Shares of Goldcorp Inc. (NYSE:GG), lost -0.28% to $17.76.
At one point, during Friday trade, Goldcorp’s shares were climbing, as gold prices edged up from the preceding session’s two and a half week low on a softer dollar, according to Reuters.
The dollar is weaker due to uncertainty over Greece’s debt talks, Reuters noted.
Spot gold was nearly changed at $1,189.51 an ounce, while U.S. gold futures for August delivery was up 0.07% to $1,189.60 an ounce as of 1:21 p.m. ET Friday.
Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. The company primarily explores for gold, silver, copper, lead, and zinc deposits.
Finally, Teck Resources Limited (NYSE:TCK), ended its last trade with -3.96% decline, and closed at $11.64.
Teck Resources Limited, said on Thursday it will suspend production at its six Canadian steelmaking-coal mines for about three weeks in the third quarter so that it can align output and inventory with changing coal market conditions, according to Reuters.
The Canadian miner said it will consider additional production adjustments over the course of 2015.
“Rather than push incremental tonnes into an over-supplied market, we are taking a disciplined approach to managing our mine production in line with market conditions,” Chief Executive Don Lindsay said in a statement.
The move will reduce third-quarter production by about 1.5 million tonnes, or 22 percent, to 5.7 million tonnes, with sales seen in the range of 6 million to 6.5 million tonnes.
Annual coal production is now estimated at 25 million to 26 million tonnes, down from a February forecast of 26.5 million to 27.5 million tonnes. Reuters Reports.
Teck Resources Limited explores, develops, and produces natural resources in the Americas, the Asia Pacific, Europe, and Africa. Its principal products comprise copper, counting copper concentrates and cathode copper; steelmaking coal; and refined zinc and zinc concentrates.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
